Recent OKYO News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2024 01:00:29 PM
- OKYO Pharma CEO Interview to Air on Bloomberg TV • GlobeNewswire Inc. • 08/23/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2024 11:00:07 AM
- OKYO Pharma Announces Chairman Acquires Shares • GlobeNewswire Inc. • 08/23/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 11:00:14 AM
- OKYO Pharma Announces Chairman Acquires Shares • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 05:21:25 PM
- OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference • GlobeNewswire Inc. • 08/15/2024 04:13:50 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:51 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/06/2024 11:00:33 AM
- OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 07/31/2024 09:00:29 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/11/2024 11:00:09 AM
- OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/10/2024 11:00:33 AM
- OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease • GlobeNewswire Inc. • 07/10/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/10/2024 10:50:29 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:00:21 AM
- OKYO Pharma Announces Participation in May 2024 Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 • GlobeNewswire Inc. • 04/08/2024 11:00:00 PM
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 • GlobeNewswire Inc. • 03/22/2024 11:00:00 AM
- OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM